Dr. Ehlers is Deputy Director of the Clinical Trials Group of the Immune Tolerance Network (ITN), a clinical research consortium funded by the NIH, whose mission is to accelerate the clinical development of immune tolerance therapies in autoimmunity and other areas, with a special focus on type 1 diabetes (T1D). Dr. Ehlers leads the T1D portfolio of clinical trials at the ITN, including the AbATE, START, RETAIN, and T1DAL trials. Dr. Ehlers is a physician-scientist with 18 years of experience in academic research and 10 years of biopharmaceutical industry experience in basic and clinical translational research. Therapeutic areas include diabetes, autoimmunity, and CVD. Prior to 2008, Dr. Ehlers was Chief Medical Officer (CMO) at Pacific Biomarkers, Inc. (2002-2008) and CMO at Restoragen, Inc. (1998-2002). He was formerly Chairman of the Department of Medical Biochemistry at the University of Cape Town Medical School (1992-1998) and Instructor in Biochemistry at Harvard Medical School (1989-1992).